Evelo Biosciences, Inc., a biotechnology company, discovers and develops oral biologics for the treatment of inflammatory diseases and cancer. It is developing EDP1815, a whole-microbe candidate for the treatment of inflammatory diseases; and is in clinical development trial for the treatment of psoriasis and atopic dermatitis, as well as for the hyperinflammatory response associated with COVID-19. The company also engages in developing EDP1867, an inactivated investigational oral biologic for the treatment of inflammatory diseases; EDP2939, an extracellular vesicle investigational oral biologic for the treatment of inflammatory diseases; and EDP1908, a product candidate for oncology. Evelo Biosciences, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.
IPO Year: 2018
Exchange: NASDAQ
Website: evelobio.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 11/2/2021 | $44.00 → $41.50 | Market Outperform | JMP Securities |
| 11/1/2021 | $12.00 | Neutral → Buy | Chardan Capital Markets |
| 6/23/2021 | $36.00 → $38.00 | Market Outperform | JMP Securities |
| 6/23/2021 | $28.00 | Overweight | Cantor Fitzgerald |
EFFECT - Evelo Biosciences, Inc. (0001694665) (Filer)
15-12G - Evelo Biosciences, Inc. (0001694665) (Filer)
S-8 POS - Evelo Biosciences, Inc. (0001694665) (Filer)
S-8 POS - Evelo Biosciences, Inc. (0001694665) (Filer)
8-K - Evelo Biosciences, Inc. (0001694665) (Filer)
POS AM - Evelo Biosciences, Inc. (0001694665) (Filer)
25-NSE - Evelo Biosciences, Inc. (0001694665) (Subject)
DEFA14A - Evelo Biosciences, Inc. (0001694665) (Filer)
DEF 14A - Evelo Biosciences, Inc. (0001694665) (Filer)
8-K - Evelo Biosciences, Inc. (0001694665) (Filer)
JMP Securities reiterated coverage of Evelo Biosciences with a rating of Market Outperform and set a new price target of $41.50 from $44.00 previously
Chardan Capital Markets upgraded Evelo Biosciences from Neutral to Buy and set a new price target of $12.00
JMP Securities reiterated coverage of Evelo Biosciences with a rating of Market Outperform and set a new price target of $38.00 from $36.00 previously
Cantor Fitzgerald initiated coverage of Evelo Biosciences with a rating of Overweight and set a new price target of $28.00
Morgan Stanley reiterated coverage of Evelo Biosciences with a rating of Equal-Weight and set a new price target of $13.00 from $14.00 previously
Jefferies upgraded Evelo Biosciences from Hold to Buy and set a new price target of $18.00 from $11.00 previously
Chardan Capital reiterated coverage of Evelo Biosciences with a rating of Neutral and set a new price target of $15.00 from $10.00 previously
JMP Securities reiterated coverage of Evelo Biosciences with a rating of Outperform and set a new price target of $36.00 from $27.00 previously